Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
about
Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.Immune correlates of clinical outcome in melanoma.Chimeric antigen receptor transduced T cells: Tuning up for the next generation.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
P2860
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Current status of chimeric ant ...... -based cancer immunotherapies.
@en
Current status of chimeric ant ...... -based cancer immunotherapies.
@nl
type
label
Current status of chimeric ant ...... -based cancer immunotherapies.
@en
Current status of chimeric ant ...... -based cancer immunotherapies.
@nl
prefLabel
Current status of chimeric ant ...... -based cancer immunotherapies.
@en
Current status of chimeric ant ...... -based cancer immunotherapies.
@nl
P2860
P921
P1476
Current status of chimeric ant ...... -based cancer immunotherapies.
@en
P2093
Bijay Mukherji
Upendra P Hegde
P2860
P2888
P356
10.1007/S00262-017-2007-X
P5008
P577
2017-05-11T00:00:00Z
2017-09-01T00:00:00Z